Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study

被引:15
|
作者
Engelberger, Rolf P. [1 ,2 ,3 ]
Noll, Georg [4 ]
Schmidt, Dominique
Alatri, Adriano [1 ]
Frei, Benedikt
Kaiser, Walter E. [5 ]
Kucher, Nils [2 ,3 ,6 ]
机构
[1] CHU Vaudois, Div Angiol, CH-1011 Lausanne, Switzerland
[2] Inselspital Bern, Univ Hosp, Swiss Cardiovasc Ctr, Clin Angiol, Bern, Switzerland
[3] Univ Bern, CH-3012 Bern, Switzerland
[4] Klin Hirslanden, HerzKlin, Zurich, Switzerland
[5] DocWorld AG, Menzingen, Switzerland
[6] Univ Hosp, Inselspital, Swiss Cardiovasc Ctr, Clin Cardiol, Bern, Switzerland
关键词
Atrial fibrillation; Primary care; Rivaroxaban; Stroke prevention; Treatment satisfaction; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; TREATMENT SATISFACTION; ORAL ANTICOAGULATION; WARFARIN; RISK; DABIGATRAN; ADHERENCE; MANAGEMENT; PHYSICIANS;
D O I
10.1016/j.ejim.2015.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known. Methods: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up. Results: We enrolled 537 patients (73 +/- 11 years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2 +/- 1.3 and 2.4 +/- 1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naive (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6 +/- 1.4 under VKA to 5.5 +/- 0.8 points (P < 0.001), and overall physician satisfaction from 3.9 +/- 1.3 to 5.4 +/- 0.9 points (P < 0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4 +/- 0.9) and physician's satisfaction (5.5 +/- 0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95% CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95% CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95% CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason. Conclusion: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 50 条
  • [11] Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients
    Ke, Hong-hong
    He, Yan
    Lv, Xiang-wei
    Zhang, En-Hao
    Wei, Zhe
    Li, Jin-yi
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (02) : 270 - 276
  • [12] Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry
    Caro Martinez, Cesar
    Cerezo Manchado, Juan Jose
    Flores Blanco, Pedro Jose
    Elvira Ruiz, Gines
    Albendin Iglesias, Helena
    Lova Navarro, Alejandro
    Arregui Montoya, Francisco
    Garcia Alberola, Arcadio
    Pascual Figal, Domingo Andres
    Bailen Lorenzo, Jose Luis
    Navarro-Almenzar, Begona
    Garcia-Candel, Faustino
    Manzano Fernandez, Sergio
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (08) : 1463 - 1471
  • [13] Antithrombotic therapy in nonvalvular atrial fibrillation: problems and prospects
    Rychkov, A. Y.
    Khor'kova, N. Y.
    Bliznyakov, A. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2010, 6 (04) : 522 - 527
  • [14] Antithrombotic Therapy in Nonvalvular Atrial Fibrillation: Consensus and Challenges
    Khattak, Furqan
    Alam, Mian B.
    Paul, Timir K.
    Rijal, Shasank
    Wazir, Shoaib
    Lavie, Carl J.
    Saba, Samir
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2018, 355 (05): : 467 - 476
  • [15] RIVAROXABAN IN PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION
    Simonyi Gabor
    Medvegy Mihaly
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2012, 65 (11-12): : 365 - 368
  • [16] Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster randomized trial
    Lee, Theresa M.
    Ivers, Noah M.
    Bhatia, Sacha
    Butt, Debra A.
    Dorian, Paul
    Jaakkimainen, Liisa
    Leblanc, Kori
    Legge, Dan
    Morra, Dante
    Valentinis, Alissia
    Wing, Laura
    Young, Jacqueline
    Tu, Karen
    IMPLEMENTATION SCIENCE, 2016, 11
  • [17] Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
    Laliberte, Francois
    Cloutier, Michel
    Crivera, Concetta
    Nelson, Winnie W.
    Olson, William H.
    Schein, Jeffrey
    Vanderpoel, Julie
    Germain, Guillaume
    Lefebvre, Patrick
    ADVANCES IN THERAPY, 2015, 32 (03) : 216 - 227
  • [18] Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation
    Coleman, Craig, I
    Thompson, Stanley
    Ashton, Veronica
    Palladino, Michael
    Bunz, Thomas J.
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2020, 112 (04) : 395 - 401
  • [19] ANTICOAGULANT THERAPY IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION
    Belenkov, Yu. N.
    Shakaryants, G. A.
    Khabarova, N., V
    An, G., V
    KARDIOLOGIYA, 2018, 58 (10) : 45 - 52
  • [20] The Efficacy of Rivaroxaban in Patients With Atrial Fibrillation
    Carag, Michael R.
    Arora, Rohit R.
    AMERICAN JOURNAL OF THERAPEUTICS, 2014, 21 (05) : 412 - 418